in vivo CAR-T大火，UCAR-T真被抛弃了？不，它只是换了身“装备”

Core Viewpoint - The article discusses the evolution and differentiation of CAR-T cell therapy, highlighting the challenges of autologous CAR-T and the emergence of allogeneic UCAR-T and in vivo CAR-T as key development directions in the industry [2][3][25]. Group 1: CAR-T Technology Development - Autologous CAR-T therapy has established clinical value but faces significant limitations such as long production cycles, high costs, and manufacturing failures [2][8]. - Allogeneic UCAR-T offers a solution to these challenges by using healthy donor cells, allowing for immediate availability, cost control, and enhanced safety [2][10]. - In vivo CAR-T, which generates CAR-T cells directly within the patient, is gaining attention for its potential to reduce treatment time and costs, although it is still in early exploration stages [3][9]. Group 2: Technical Pathways and Maturity - The CAR-T field has three distinct technical pathways: autologous CAR-T, in vivo CAR-T, and UCAR-T, each with unique advantages and limitations [6][7]. - Autologous CAR-T is commercially mature but has significant bottlenecks, while in vivo CAR-T is a hot topic but faces technical challenges and is still in early clinical exploration [8][9]. - UCAR-T is evolving through technological iterations, addressing early challenges such as immune rejection and storage issues, and is becoming a critical pathway in CAR-T development [10][13]. Group 3: UCAR-T's Technological Iteration - Early UCAR-T faced issues like immune rejection and short in vivo persistence, but advancements in gene editing technologies are overcoming these hurdles [14][15]. - Innovative strategies such as "disguise" and "counterattack" are being developed to enhance the persistence and efficacy of UCAR-T cells [15][16]. - The strategic knockout of HLA molecules is emerging as a key innovation to address immune rejection, significantly improving the clinical applicability of UCAR-T [16]. Group 4: Market Opportunities and Challenges - The field of autoimmune diseases presents a significant opportunity for UCAR-T, as it aligns well with the challenges of obtaining high-quality autologous T cells [17][19]. - Domestic companies are advancing UCAR-T therapies into clinical stages for autoimmune diseases, positioning themselves in a less competitive market compared to blood cancers [17][19]. - The safety and tolerability of UCAR-T in autoimmune patients are critical metrics for assessing its maturity and potential market success [20][21]. Group 5: Future Outlook and Value Proposition - The coexistence of autologous CAR-T, UCAR-T, and in vivo CAR-T reflects a layered approach to meet diverse clinical needs, with UCAR-T focusing on accessibility and standardization [23][25]. - 2026 is anticipated to be a pivotal year for validating the clinical value of UCAR-T, with several companies expected to release important clinical data [23][25]. - The balance of safety, durability, and accessibility will be central to the competitive landscape of CAR-T therapies, with UCAR-T providing a clearer risk-reward structure [25][26].